Genomic instability and mutations are fundamental aspects of human malignancies, leading to progressive accumulation of the hallmarks of cancer. For some time, it has been clear that key mutations may be used as both prognostic and predictive biomarkers, the best-known examples being the presence of germline BRCA1 or BRCA2 mutations, which are not only associated with improved prognosis in ovarian cancer, but are also predictive of response to poly(ADP-ribose) polymerase (PARP) inhibitors. Although biomarkers as specific and powerful as these are rare in human malignancies, next-generation sequencing and improved bioinformatic analyses are revealing mutational signatures, i.e. broader patterns of alterations in the cancer genome that have the power to reveal information about underlying driver mutational processes. Thus, the cancer genome can act as a stratification factor in clinical trials and, ultimately, will be used to drive personalized treatment decisions. In this review, we use ovarian high-grade serous carcinoma (HGSC) as an example of a disease of extreme genomic complexity that is marked by widespread copy number alterations, but that lacks powerful driver oncogene mutations. Understanding of the genomics of HGSC has led to the routine introduction of germline and somatic BRCA1/2 testing, as well as testing of mutations in other homologous recombination genes, widening the range of patients who may benefit from PARP inhibitors. We will discuss how whole genome-wide analyses, including loss of heterozygosity quantification and whole genome sequencing, may extend this paradigm to allow all patients to benefit from effective targeted therapies. 
Introduction
The integrity of the genome is essential for ensuring survival of cells and organisms. However, genomes are constantly at risk from both intracellular and extracellular agents, such as by-products of cellular metabolism, radiation or chemical exposure, and spontaneous DNA mutation events. Thus, cells have evolutionarily conserved mechanisms of DNA repair and maintenance that can cope with these threats to their genetic material, while also allowing some mutational alterations to be transferred to their progeny as part of the process of adaptation and evolution [1] . Although this evolution is most obvious at the level of species, it is also visible within the adaptive immune system, which relies on somatic recombination to generate the diverse range of antibodies and immune cell receptors required to combat pathogens and cellular defects [2] . These processes are normally highly regulated, to ensure effective development of the immune system while also preventing genomic instability that may lead to hyperactive evoluGenomic instability and mutations are now considered to be key enabling characteristics of cancer, promoting the stepwise accumulation of the hallmarks of malignant cells, including sustained proliferative signalling, resistance to cell death, evasion of growth suppressors, replicative immortality and induced angiogenesis, and invasive and metastatic capabilities [4, 5] . Genomic instability can also contribute to the ability of some cancers to evade the immune response, and to even promote inflammation that is beneficial to the proliferation and spread of the cancer, effectively enabling hijacking of the immune system [6] .
Nonetheless, DNA repair defects that result in tumour-enhancing genomic instability can also act as an Achilles heel of that cancer, and underpin novel targeted therapies that exploit either production of immunogenic neoantigens that prime tumours for treatment with immunotherapy [7] , or DNA double-strand break (DSB) repair deficiencies that are enriched in certain cancer types and can be targeted by DNA repair inhibitors [8] . Unfortunately, the same DNA repair defects that can sensitize cancer cells to these therapies also drive diversity and provide possible escape pathways leading to therapeutic resistance.
This review will examine the use of the cancer genome as a predictive biomarker in the context of DNA DSB repair-defective cancers, specifically homologous recombination (HR)-deficient ovarian cancer (OC), and DNA repair inhibitor therapies that exploit these defects.
DNA DSB repair pathways
DNA DSBs consitute the most dangerous type of lesions that DNA can sustain, because just a single unrepaired DSB can be sufficient to trigger cell death [9] . This highlights the enormous dependency for cell survival on the capacity of a cell to repair DNA. When DNA DSBs form, there are several competing pathways that can take over their repair. The choice of DNA DSB repair mechanism employed by a cell is complex [10] , and depends on multiple factors, including the complexity of damaged DNA DSB ends (one-ended; two-ended; four-ended) [11] , the stage of the cell cycle, and the specific activity of nucleases such as MRE11 [12] . In the context of cancer, however, the mode of DNA repair also crucially depends upon which DNA repair pathways remain intact in that cancer at that time.
HR and classic non-homologous end joining (C-NHEJ) are the two main DNA DSB repair pathways available in mammalian cells (Figure 1 ). The contributions of other DNA DSB pathways, such as alternative end-joining and single-strand annealing, which were long believed to play back-up roles, are now also being recognized as significant [10] . HR DNA repair is considered to be of high fidelity, as it relies on the presence of a sister chromatid to act as a template for repair, and results in largely error-free repair. This use of a sister chromatid means that HR can only occur during the S and G 2 phases of the cell cycle following DNA replication. Furthermore, the crucial HR genes BRCA2 and RAD51 are only expressed during S/G 2 , again ensuring that HR cannot occur in G 0 /G 1 [13] . In contrast, C-NHEJ can occur throughout the cell cycle, and dominates in G 0 /G 1 and early G 2 . It is not homology-directed, and is a more error-prone DNA repair pathway than HR, causing chromosomal rearrangements and mutations when not regulated [10, 14, 15] . Therefore, HR deficiency (HRD), defined as a loss of HR DNA repair capacity, is associated with genomic instability leading to increased genome-wide losses of heterozygosity (LOHs) [16, 17] , sometimes called 'genomic scarring' [18] . Loss of HR DNA repair is frequently observed in human malignancies, including ovarian high-grade serous carcinoma (HGSC), triple-negative breast cancer (TBNC), and prostate cancer [19] [20] [21] , and will be discussed below. The consequences of C-NHEJ pathway loss are more complex, and lie beyond the scope of this review. Here, we will focus on HRD, given its prevalence in human malignancies and the promising targeted therapeutic opportunities now available.
BRCA1/2 defects in high-grade epithelial OC
BRCA1 and BRCA2 were first identified as breast cancer susceptibility genes in 1994 and 1995, respectively [22] [23] [24] , and play fundamental roles in HR [25, 26] . BRCA1 has multiple roles, but importantly it assists with recruitment of other DNA repair proteins, including BRCA2, to sites of DNA DSB. BRCA2 is then able to catalyse the formation of RAD51 filaments, thereby initiating strand invasion of the sister chromatid and homology-directed repair [27, 28] . For a more detailed review of the HR DNA repair pathway, see [29] .
So far, the clinical importance of BRCA1/2 mutations has had the greatest impact in the management of OC. Although cervical cancer is the commonest gynaecological malignancy worldwide, and endometrial cancer the commonest gynaecological malignancy in Western countries, OC remains a significant clinical problem, with little improvement in overall survival in the past 20 years [30] . Long thought to be a single disease, OC is now recognized to be at least five separate diseases (HGSC, low-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, and mucinous carcinoma), driven by different genomic aberrations and with different cells of origin, and linked only by their broad anatomical location [30] . HGSC is the commonest subtype -approximately 70% of OC cases and 80% of OC deaths are due to HGSC -and typically presents at an advanced stage, when treatment is rarely curative [31] . HGSC, endometrial cancer and cervical cancer have allPredictive genomic biomarkers in cancer 589 and copy number (CN)-high endometrial cancer, as both have near-universal TP53 mutation and extensive CN alterations (CNAs) [33] .
It has been estimated that approximately half of all HGSCs contain defects in HR at the time of diagnosis [21, 34] , the commonest causes of which are either germline BRCA mutation (approximately 8-12% for BRCA1 and 5-7% for BRCA2) or somatic BRCA mutation (approximately 3% for both BRCA1 and BRCA2) [21, 35, 36] . A further 5-20% of HGSCs are HR-deficient, owing to epigenetic silencing of BRCA1 via promoter hypermethylation, which is considered to be mutually exclusive with BRCA1/2 mutations [21, 37] . Conversely, BRCA2 promoter hypermethylation is rare in HGSC, and, unlike BRCA1 promoter hypermethylation, does not correlate with reduced mRNA expression [38] . In a recent study of nearly 10 000 BRCA carriers, the cumulative risks of developing OC prior to age 80 years were estimated to be 44% [95% confidence interval (CI) 36-53%] for BRCA1 and 17% (95% CI 11-25%) for BRCA2 [39] , highlighting the importance of these genes in the development of OC.
Therapeutic exploitation of HR DNA repair defects in OC
The exciting finding that inhibition of poly(ADP-ribose) polymerase (PARP) 1 is cytotoxic to BRCA1/2-null cells in vitro [40, 41] led to the subsequent development of PARP inhibitors as a new class of targeted anticancer drugs for HR-deficient cancers, initially only for tumours lacking BRCA1/2 function. This specific sensitivity of BRCA1/2-mutated cells to PARP inhibition is an excellent manifestation of the concept of 'synthetic lethality'. This term was first used in the 1940s in relation to Drosophila [42] , and describes the phenomenon whereby deletion or inactivation of two genes is lethal when deletion of either one alone is not (Figure 2 ). Further examples of this phenomenon in relation to DNA damage repair are reviewed in [8] .
Over the past decade, multiple clinical studies have shown that tumours harbouring BRCA1/2 mutations are sensitive to PARP inhibitors and platinum-based chemotherapy, and are associated with improved overall survival, especially BRCA2 mutant cases [43] . As a result, BRCA1/2 mutation testing has become routine in the clinical management of OC patients, as well as a key stratification factor in clinical trials. Despite the high frequency of BRCA1 methylation in high-grade serous OC, its impact on platinum or PARP inhibitor responses has not been established, with mixed reports on its effects on overall survival in clinical studies [18, 21, 44] .
Olaparib (Lynparza; AstraZeneca) was the first PARP inhibitor to be approved both by the US Food and Drug Administration and by the European Medicines Agency (EMA), and, since December 2014, it has been used to treat relapsed OC with both germline and somatic BRCA1/2 mutations. Olaparib was also approved by Australia's Therapeutic Goods Administration in January 2016, and, since February 2017, has been reimbursed by the Pharmaceutical Benefits Scheme, with the approval being restricted tightly to germline BRCA1/2-mutated HGSC in the maintenance setting. Additional PARP inhibitors, including niraparib (Zejula; Tesaro) and rucaparib (Rubraca; Clovis Oncology), have also been approved in the USA for the treatment of, respectively, recurrent OC in the maintenance setting after successful treatment with platinum-based chemotherapy, and as single-agent treatment for those with proven BRCA1/2-mutated OC. Although they have not yet been approved by the EMA, both Tesaro and Clovis Oncology have applied for licences to sell within Europe.
HR defects beyond BRCA1/2 in high-grade epithelial OC
Although loss of BRCA1 or BRCA2 function through mutation or epigenetic alteration is the commonest cause of defective HR, the efficacy of PARP inhibitor therapy has also been demonstrated in cells with loss of other HR proteins, a trait sometimes described as 'BRCAness' [45, 46] . As stated above, it has been estimated that approximately half of HGSCs contain defects in HR DNA repair at the time of diagnosis [21, 34] , of which germline or somatic BRCA1/2 mutations account for 20%. The TGGA Network study attributed the remaining 30% to other alterations, including mutations in Fanconi anaemia genes (FANCC, FANCD2, FANCA, FANCE, FANCI, FANCL, and FANCM), other genes associated with DNA damage repair and genome stability (ATM, ATR, CHEK2, NBN, PALB2, RAD50, and RAD51), BRCA1 promoter hypermethylation, EMSY amplification, and loss of PTEN [21] .
Many DNA repair genes have been associated with PARP inhibitor synthetic lethality when deficient in vitro or in vivo (Table 1) . However, more consistent evidence of HR involvement and PARP inhibitor sensitivity is available for ATM [47, 48] , RAD51C [18, 48, 49] , RAD51D [49] , NBN [18] , and PALB2 [50] . On the other hand, there appears to be conflicting evidence for the involvement of PTEN loss [51, 52] and EMSY amplification [53] . Interestingly, many HGSCs will show a BRCA mutant-like phenotype, despite the absence of other known HR gene mutations [17, 18, 54] .
Limitations of HR DNA repair gene testing
In keeping with the preclinical data, a key finding in early-phase trials of PARP inhibitors was that some patients lacking a germline or somatic mutation in BRCA1/2 derived marked clinical benefit [55] . This implied that extending mutation testing beyond BRCA1/2 to include a wider panel of HR genes might have utility, and could potentially identify a greater number of patients who might benefit from PARP inhibitor therapy. However, germline/somatic mutations in other core HR genes are detected in <10% of relapsed HGSCs, and these panels are also unable to detect promoter methylation, which requires additional tests such as pyrosequencing or methylation-specific polymerase chain reaction. Thus, simply sequencing a wide panel of HR genes may still fail to detect all patients who could derive benefit from PARP inhibitor therapy [17, 18, 54] . Furthermore, despite extensive characterization and diagnostic testing of BRCA1 and BRCA2 for pathogenic (class 4-5) variants, there are still many variants of uncertain significance (VUSs) (class 2-3) within these genes that remain to be clarified [56] . These variants pose a significant problem in the clinic, as their effects on disease risk and treatment response are undetermined, and their identification often necessitates both functional experimental analysis [57] and complex discussions with patients and their families. As next-generation sequencing (NGS) costs continue to decline, and somatic and germline testing become more prevalent, an increasing number of VUSs are being detected, and an increasing number of other less well-characterized genes are being screened [58] . One very specific use for HR gene sequencing is to identify secondary or reversion mutations that correct the primary HR gene defects, which constitute a known mechanism of HR repair rescue and PARP inhibitor/platinum resistance. These secondary and reversion mutations are the best-studied mechanisms of HR repair rescue and PARP inhibitor/platinum resistance. Secondary mutations have been described in BRCA1/2 and RAD51C/D in recurrent HGSC and prostate cancer patients, and appear to be enriched in patients with acquired platinum resistance rather than primary resistance [49, 59, 60] . However, not all cases of PARP inhibitor and platinum resistance can be explained by secondary and reversion mutations. Cruz et al [61] recently reported the presence of RAD51 foci, which represent a marker of functional HR DNA repair, in BRCA1 mutant and BRCA2 mutant breast cancer and OC PDX models, despite no secondary mutations being detected. Indeed, multiple alternative mechanisms of HR restoration have been reported [62] [63] [64] that will not be detected with HR gene sequencing. Two genes of specific note are 53BP1 and REV7. In the context of DNA DSBs, 53BP1 can promote non-homologous end joining and suppress HR, acting in opposition to BRCA1 by preventing DSB end-resection [65] . Crucially, loss of 53BP1 function permits restoration of HR repair in cells lacking BRCA1 [62, 66] and induces resistance to PARP inhibition [63] . More recently, REV7 (also known as MAD2L2) has been shown to work downstream of 53BP1 to coordinate DSB pathway choice, whereas loss of REV7 restores HR in BRCA1-deficient cells, leading to PARP inhibitor resistance [64] . In addition, refolding of BRCA1 into an HR-competent conformation can restore HR function and thus induce PARP inhibitor resistance [67] . However, the specific contributions of these mechanisms to clinical drug resistance remain to Predictive genomic biomarkers in cancer 591 be determined. Nonetheless, these novel mechanisms highlight the fact that, although HR gene sequencing panels can detect some resistance events, other correcting mutations or deletions may be missed, along with alternative mechanisms of restored HR.
Given the potential shortcomings of relying solely on HR gene sequencing, novel strategies to use genomic alterations as prognostic and predictive biomarkers have been developed in parallel.
Genome-wide biomarkers of HRD
The mutations and CNAs within a cancer genome act as an archaeological record of all of the unrepaired insults that have accumulated during the evolution of that tumour. It has been known for some time that specific carcinogenic processes in certain tumours, such as ultraviolet light in skin cancer or tobacco exposure in lung cancer, give rise to specific patterns of base-pair mutations. Although the majority of mutations observed in cancer are not driver mutations, these passenger mutations are frequent and can be informative of the underlying mutational process [68] . However, it is only recently that the application of unsupervised methods to large quantities of NGS data have permitted the identification of distinct mutational landscapes (or 'mutational signatures') in malignancies that lack obvious aetiologies. This can include cancers that may be defective in HR through a variety of mechanisms. In addition, methods to analyse and categorize the complex CN and structural variant (SV) alterations are now available, some of which may have immediate clinical utility.
Single-nucleotide variant (SNV) signatures
Using nearly 5 million somatic substitutions and small insertions/deletion (indels) identified in whole genome sequencing (WGS) and whole exome sequencing (WES) data from >7000 primary tumours, Alexandrov et al studied the six classes of SNV (C > A, C > G, C > T, T > A, T > C, and T > G), as well as the nucleotides immediately 5 ′ and 3 ′ to each mutated base, thus analysing 96 possible classes of nucleotide change. They identified 21 distinct SNV signatures across 30 different cancer types [69] . Key points were that all signatures contained multiple different classes of nucleotide change, and that multiple different signatures could be identified in any given tumour type. Nonetheless, it was clear that SNV signature 3, which was characterized by a large number of indels (up to 50 bp) rather than specific nucleotide changes, was strongly associated with the presence of BRCA1/2 mutations. In addition, there were breast, ovarian and pancreatic cancers whose genomes contained a significant contribution from SNV signature 3 but that lacked mutations in either of these genes. This suggested that SNV signature 3 might represent a genomic hallmark of defective HR that could potentially be applied to tumours both with and without known BRCA1/2 mutations. However, it has yet to be demonstrated that the presence of this signature as such is either prognostic or can predict response to therapy in patients, although, in oesophageal cancer, mutational signatures that defined three broad disease subgroups had some predictive ability in cell line models [70] . Oesophageal cancer is a good example, along with HGSC and TNBC, of cancers that are dominated by CN changes [71] , and that are generally difficult to classify through mutational signatures, as they have relatively low mutational burdens, low rates of driver oncogenic mutations, and highly complex genomic profiles [72] . Alternative strategies are required to analyse their genomes more comprehensively.
LOH assays
One genomic consequence of loss of HR is loss or duplication of chromosomal regions, also known as genomic LOH [16, 17] . LOH was first investigated following reports of increased CN alterations in HR-deficient cancers [73, 74] , and this feature of HR-deficient cancers is now being explored as a potential predictive biomarker.
Recently, the phase 2 trial of rucaparib [Assessment of Rucaparib In Ovarian Cancer Trial (ARIEL2) phase 2] demonstrated the utility of an LOH signature as a surrogate marker of HRD to identify BRCA wild-type (WT) HGSC patients who may benefit from PARP inhibitor therapy [18] . NGS was used to measure the percentage of genome-wide LOH in tumours, using 3500 single-nucleotide polymorphisms. A cut-off of 14% LOH was initially used to define HRD. In the first part of ARIEL2, patients with HGSC relapsing in the platinum-sensitive time frame (i.e. >6 months following the last application of platinum chemotherapy) were categorized into three groups -BRCA mutant, BRCA WT LOH high, and BRCA WT LOH low. All patients received single-agent rucaparib (600 mg twice daily until disease progression), with a primary endpoint of progression-free survival (PFS). The trial met its primary endpoint, as PFS was significantly longer in the BRCA mutant group (hazard ratio 0.27, 95% CI 0.16-0.44, P < 0.0001) and BRCA WT LOH high group (hazard ratio 0.62, 95% CI 0.42-0.90, P = 0.011) than in the BRCA WT LOH low subgroup. Response rates were higher in the BRCA mutant group (80%, 95% CI 64-91) than in the BRCA WT LOH high group (29%; 95% CI and in the in the BRCA WT LOH low group (10%; 95% CI [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Interestingly, in those who did respond, median response durations were similar in the BRCA mutant LOH high group (9.2 months, 95% CI 6.4-12.9) and BRCA WT LOH high groups (10.8 months, 95% CI 5.7-not reached), and both were higher (P = 0.013 and P = 0.022, respectively) than in the LOH low subgroup (5.6 months, 95% CI 4.6-8.5).
In the follow-on randomized phase 3 ARIEL3 study, women responding to platinum chemotherapy in the relapsed setting were randomized to receive rucaparib (600 mg twice daily or placebo) until disease progression, with, again, stratification into the three subgroups 592 K Nesic et al Figure 3 . Tandem duplications and FBIs. The figure shows highly simplified representations of complex genomic rearrangements that are observed in many malignancies. In both cases, there is duplication of a genomic region. In the tandem duplicator phenotype (left), the duplicated regions lie in the same orientation; one cause of this is a restart-bypass mechanism around stalled replication forks in cells lacking BRCA1 function. In FBIs (right), a DNA DSB in G 0 /G 1 is replicated in S phase, creating two duplicated end sequences that are fused together in opposite orientations, possibly as a result of breakage-fusion-bridge cycles.
described in ARIEL2. However, a refined 16% LOH cut-off was utilized [75] . Outcomes were best in the BRCA mutant group: the median PFS for those treated with rucaparib was 16.6 months (95% CI 13.4-22.9), as compared with 5.4 months (95% CI 3.4-6.7) in those treated with placebo (hazard ratio 0.23, P < 0.0001). Positive results were also seen in both the HR-deficient population (BRCA mutant and BRCA WT LOH high) and the overall intention-to-treat population. However, interestingly, even in the BRCA WT LOH low group, rucaparib treatment induced a significant improvement in PFS as compared with placebo: 6.7 months (95% CI 5.4-9.1) versus 5.4 months (95% CI 4.1-5.7), respectively (hazard ratio 0.58, 95% CI 0.40-0.85; P = 0.0049).
The randomized, placebo-controlled, phase 3 trial of the PARP inhibitor niraparib [76] also grouped patients on the basis of germline BRCA status by using BRACAnalysis CDx (Myriad Genetics, Salt Lake City, UT, USA), and further stratified the germline BRCA WT group on the basis of their HRD status by using the myChoice HRD test (Myriad Genetics) -this test combines quantification of LOH, telomeric allelic imbalance, and large-scale state transitions [77, 78] . Again, PARP inhibitor treatment induced a highly significant improvement in PFS in the germline BRCA mutant group (21.0 versus 5.5 months, hazard ratio 0.27; 95% CI 0.17-0.41), but, as in ARIEL3, results in the BRCA WT HRD-negative cohort indicated a significant improvement in PFS (6.9 versus 3.8 months, hazard ratio 0.58; 95% CI 0.36-0.92) for those treated with niraparib as compared with placebo.
Thus, the two LOH-based biomarkers, although being potentially useful in predicting outcome to PARP inhibitor therapy as a single-agent treatment, lacked specificity, and were not able to override the power of platinum response as a surrogate marker for maintenance of PARP inhibitor benefit in the relapsed setting. There are additional limitations to the use of LOH assays as a biomarker, in particular the fact that genomic scarring does not disappear if the HR pathway is restored, highlighting it as a historical marker of defective DNA repair, rather than a reflection of the current DNA repair capacity of a tumour. For example, in ARIEL2 part 1, LOH analyses were undertaken in matched tumour samples from 117 patients at the time of diagnosis and at study entry. Although there was a strong correlation (rho = 0.86, P < 0.0001) between archival and study-entry tumour samples, of the 50 cases classified as LOH low at the time of diagnosis, 17 (34%) were LOH high at relapse, whereas no cases changed from LOH high at diagnosis to LOH low at relapse [18] . For this reason, LOH assays may be most useful in first-line trials of untreated OC that have had no prior exposure to any chemotherapy and in which acquired resistance has not yet developed. However, in relapsed cases, combining LOH assays with other methods to measure HR capacity may provide better predictive power.
Complex genomic algorithms including SV and CN signatures
Further analyses of the genomes of ovarian, breast and other cancer types are revealing signatures within the complex SVs and CN variants that have the potential to act as tools for stratification within clinical trials and to direct therapy.
Analysis of genomic rearrangements identified in WGS data from 560 breast cancer samples, based upon 32 separate features (including clustered versus non-clustered change; deletions versus inversions versus tandem duplications; size of rearrangement; and the presence of interchromosomal translocations) revealed six rearrangement signatures [79] . Interestingly, three of these rearrangement signatures were associated with defective HR; signature 3 was associated with loss of BRCA1 (but not BRCA2) function, signature 5 was associated with loss of either BRCA1 or BRCA2 function, and signature 1, with large tandem duplications, Figure 4 . The potential of genomic biomarkers in clinical practice. Historically, patients diagnosed with HGSC were referred for BRCA1/2 testing and genetic counselling only if they had a family history of breast cancer or OC, meaning that BRCA mutations were missed in sporadic HGSC cases. Currently, all patients with HGSC should be offered germline BRCA1/2 testing regardless of family history. However, first-line treatment of HGSC is still determined by clinical factors and response to platinum chemotherapy. We suggest that extensive molecular characterization of the cancer should also be performed at the time of diagnosis, with analysis of HR gene mutations and methylation state, as well as broader genomic biomarkers. Low-cost tests could be used for this, such as sWGS, CN profiling, or LOH analysis. These would inform therapy, especially as maintenance following platinum. Following relapse, tumours could be screened for mechanisms of drug [e.g. PARP inhibitor (PARPi)] resistance in a research setting, using more in-depth molecular testing and genomic signature assessment. The results of these tests could then inform subsequent clinical decisions regarding treatment.
Leading on from this work, Serena Nik-Zainal's group then utilized deep WGS data from 22 breast cancers from women with known germline BRCA1 or BRCA2 mutations, in which LOH of the WT allele was also observed, to develop a genome-wide assay of defective HR, which they called 'HRDetect' [80] . The HRDetect score is based on the weighted quantification of six genomic features, including (in descending order of weighting) the presence of microhomology-mediated deletions, SNV signature 3, rearrangement signatures 3 and 5, widespread LOH, and SNV signature 8. When HRDetect was applied prospectively to a cohort of 560 breast cancers, it was able to detect BRCA1/2 mutations (receiver operating characteristic of 0.98) and was able to outperform LOH-based assays. Of the 560 breast cancers analysed, 124 were identified as having a high HRDetect score (>0.70), of which 47 had no detectable mutation or epigenetic alteration in BRCA1/2. In a separate OC cohort of 73 cases, 46 (63%) were predicted to have defective HR, of which 16 had no mutations in either BRCA1 or BRCA2. Together, these results reinforce the message that the cancer genome may be used as a biomarker and, specifically, that a significant proportion of cancers may have an HR-deficient phenotype without abnormalities in either BRCA1 or BRCA2. However, again like SNV signatures, HRDetect has yet to be evaluated prospectively in clinical trials.
A specific pattern of structural abnormality identified in HGSC is the tandem duplicator phenotype (Figure 3 ). This was first described in 2012 in both breast cancers and OCs as large (>100 kb) duplicated fragments, and was originally thought to be mutually exclusive with BRCA1/2 mutations [81, 82] . However, further work revealed two distributions of tandem duplications [83] ; the second group contained smaller (10 kb) fragments with microhomology breakpoints, and was associated with loss of BRCA1, but not BRCA2, function [79, 84] . Across multiple TCGA analyses, the 594 K Nesic et al tandem duplicator phenotype was identified in TBNC, HGSC and serous-like endometrial cancers, and was strongly associated with platinum sensitivity [84] . Very recently, the underlying mechanism of the smaller tandem duplications associated with BRCA1 loss has been elucidated -the duplications arise at stalled replication forks as a result of an aberrant replication restart-bypass mechanism, which terminates with end-joining [85] . Moreover, a similar pattern of duplications appears to be common across BRCA1-mutated cancers, and is also observed upon loss of BARD1 and CtBP-interacting protein (CtIP) function [85] , suggesting that identification of the tandem duplicator phenotype might be a mechanism of identifying cancers with defective DNA damage repair function.
WGS data have been used to identify other patterns in OC with potential clinical utility. The group of Shah and Huntsman undertook WGS on a large OC cohort, and identified 20 genomic features from SNV, indel, CNA and SV analyses. When they applied the data to a mixed cohort of OC subtypes (including HGSC, endometrioid carcinoma, clear cell carcinoma, and granulosa cell tumours), they identified seven distinct groups [86] . Two of these groups were composed almost exclusively of HGSC cases -an HR-deficient cohort and a cohort with a high proportion of fold-back inversions (FBIs), which are duplicated regions of the genome where the two copies face in opposing directions from the breakpoint (distinguishing them from tandem duplications; Figure 3 ) and that may arise as result of breakage-fusion-bridge cycles [87] . Again, the HR-deficient cohort contained a significant number of cases that lacked BRCA1/2 mutations. However, importantly, it was also possible to demonstrate that tumours with high FBI rates had worse prognoses than those with low FBI rates, and that FBI was associated with known poor prognostic features, including CCNE1 amplification. Thus, this assay of genome structure identified features that could act as a prognostic biomarker (high versus low FBI rate) and as a potential predictive biomarker (HRD versus non-HRD) for treatment with a PARP inhibitor. Clearly, again, this biomarker will need to be evaluated prospectively within upcoming clinical trial cohorts.
One disadvantage of rearrangement signatures, the HRDetect assay and the analysis of FBI events is the current requirement for deep-coverage WGS. It was noticeable that use of either WES data or lower-coverage WGS resulted in a significant reduction in sensitivity of the HRDetect assay [80] . Although the cost of deep WGS is falling rapidly, the requirement for relatively large quantities of DNA from fresh-frozen tumour samples, as well as the length and complexity of the bioinformatic analyses, suggests that deep WGS is likely to remain a research tool rather than a prospective clinical stratifier for some time yet.
Recently, we have used low-cost shallow WGS (sWGS) to identify CN signatures in the genomes of HGSC [88] . We used biopsy samples from the BriTROC-1 study (the first study of the UK Translational Research in Ovarian Cancer Consortium -detailed in [89] ) of relapsed HGSC, and combined relative CN data from sWGS (mean ×0.1) and TP53 mutant allele frequency from deep tagged-amplicon sequencing [90] to generate absolute CN profiles. Using non-negative matrix factorization protocols, we were able to identify distinct CN signatures in the initial cohort of 117 samples from the BriTROC-1 study, which were then validated on samples from both the Pancancer Analysis of Whole Genomes study [61] and TCGA [21] . We also undertook deep WGS on a subset of the BriTROC-1 cases to allow comparison of the CN signatures with other genomic features. We believe that there are three critical features of the CN signatures. First, they are prognostic; second, the signatures appear to correlate with other known features of HGSC genomes (for example, one CN signature is highly enriched in cases with BRCA1/2 mutation); and finally, they can be derived by the use of only 100 ng of DNA isolated from fixed tumour material [91] , and thus have the potential to be assessed in small biopsy cores. However, again, these will still need to be prospectively evaluated to assess their ultimate utility.
Conclusion
There has been enormous progress in our ability to interrogate the genomes of cancer in recent years, and with it the ability to stratify patients at the time of diagnosis. Currently, patients undergo germline BRCA1/2 mutation testing and, in some cases, NGS analysis of a wider gene panel. Our improved understanding of the mutagenic processes in cancer and their effects on the cancer genome provide powerful and cost-effective tools that have great potential for clinical utility, and so we propose a pathway (Figure 4 ) in which genomic biomarkers are incorporated routinely. As genomic scarring reflects the historical rather than the current mutational state, the role of genome-wide biomarkers should be predominantly in the analysis of newly diagnosed cancers, to determine first-line treatment approaches. With rapid and low-cost methods, ongoing monitoring of changes in genomic scarring may allow monitoring for reversion of HRD. Challenges remain in the application of genomic signatures of HRD, with prospective studies being required to optimally calibrate thresholds that correspond to each test and ultimately their clinical utility.
